Keywords: Merck, FDA, warning letter, Januvia, Janumet, lou ann Eader

Merck warned for not carrying out post-approval sitagliptin study

Article | 28 February 2012

Print This

For some time the FDA has been warning drugmakers that it will tighten up its oversight of post-marketing commitments, after ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in